⭐️ CASE-BASED INSIGHTS: With multiple JAK inhibitors now available for alopecia areata, treatment selection is becoming increasingly individualized. Read more: hubs.li/Q04Cbg7B0 #AlopeciaAreata #JAKInhibitors #HairLoss #Dermatology

📈 NEW DATA: Intismeran autogene plus pembrolizumab improved recurrence-free survival in patients with high-risk melanoma in the phase 3 INTerpath-001 trial. Read more: hubs.li/Q04CbfFP0 #Melanoma #Intismeran #Pembrolizumab #Dermatology

💡 EXPERT INSIGHTS: Menopause-related skin changes extend beyond what may be dismissed as typical aging. Read more: hubs.li/Q04Cbf8f0 #MenopauseAwarenessMonth #Menopause #SkinHealth #Dermatology

💡 EXPERT INSIGHTS: As treatment options expand across dermatology, clinicians face increasingly nuanced decisions about how to incorporate new therapies into practice. Read more: hubs.li/Q04CbczW0 #Alopecia #AtopicDermatitis #Dermatology

👥 CONFERENCE PREVIEW: From complex inflammatory disease and emerging therapies to procedural dermatology and real-world practice challenges, Horizons in Advanced Practice will tackle the issues shaping care for dermatology NPs and PAs. Read more: hubs.li/Q04CbcgR0

👥 CONFERENCE HIGHLIGHTS: Lessons from SPD 2026 highlight the importance of integrating therapeutic advances with communication, cultural competence, mental health, genetics, and other factors. Read more: hubs.li/Q04C4Hkg0 #PediatricDermatology #SPD2026 #Dermatology

📂🔎 THE DERM FILES: When is alopecia areata severe enough to warrant systemic treatment? hubs.li/Q04C4H-c0 #AlopeciaAreata #HairLoss #Dermatology

⭐️ CASE-BASED INSIGHTS: Choosing between hedgehog inhibitors for advanced basal cell carcinoma requires balancing efficacy with tolerability and a clear definition of treatment response. Read more: hubs.li/Q04C4Fy30 #BasalCellCarcinoma #BCC #Dermatology

🚨 NEW TODAY: Cosibelimab-ipdl has received an NCCN Category 2A recommendation for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. hubs.li/Q04C4Hsj0 #Cosibelimab #cSCC #SkinCancer #Dermatology

📈 NEW DATA: Lutikizumab met the primary end point in a phase 3 trial evaluating the investigational therapy in adults with moderate to severe hidradenitis suppurativa. Read more: hubs.li/Q04C4G1G0 #Lutikizumab #HidradenitisSuppurativa #HS #Dermatology

💡 EXPERT INSIGHTS: As GLP-1 medications become increasingly relevant to patients with psoriasis and obesity, identifying appropriate candidates requires individualized consideration. Read more: hubs.li/Q04BDTt-0 #GLP1 #Psoriasis #Obesity #Dermatology

💡 EXPERT INSIGHTS: GLP-1 medications may offer benefits beyond weight loss for patients living with both obesity and psoriasis. Read more: hubs.li/Q04BDSqb0 #GLP1 #Psoriasis #Obesity #Dermatology

📚STUDY FINDINGS: Dupilumab treatment was associated with a lower risk of atopic march progression in pediatric patients with atopic dermatitis. Read more: hubs.li/Q04BDQMX0 #Dupilumab #AtopicDermatitis #PediatricDermatology #Dermatology

📈 NEW DATA: Bitopertin met all primary and key secondary end points in the phase 3 APOLLO trial evaluating the investigational oral therapy in erythropoietic protoporphyria. Read more: hubs.li/Q04BxQdl0 #Bitopertin #EPP #RareDisease #Dermatology

👥 CONFERENCE HIGHLIGHTS: EADV 2026 showcased an evolving atopic dermatitis treatment landscape, with new data spanning emerging mechanisms and established targeted therapies. Read more: hubs.li/Q04BlqLf0 #AtopicDermatitis #EADV2026 #Dermatology

👥💬 Q&A: In hidradenitis suppurativa, controlling inflammation is only part of the treatment goal, preventing irreversible structural damage matters too. Read the full Q&A: hubs.li/Q04Bcdnx0 #HidradenitisSuppurativa #HS #Dermatology

In this episode of Don't Be Rash, supported by Arcutis, Lisa Swanson, MD, joins host Andrew Krakowski, MD, to discuss the often-overlooked impact of psoriasis on children’s quality of life. Watch the full episode here: hubs.li/Q04Bk_Xr0 #PediatricPsoriasis #Dermatology

🚨 BREAKING NEWS: The FDA has approved pritelivir (Hovilpri) for the treatment of refractory mucocutaneous herpes simplex virus infections in immunocompromised adults. Read more: hubs.li/Q04Blp_y0 #Pritelivir #HSV #Dermatology

📚 JOURNAL DIGEST: Catch up on the latest research shaping dermatology practice in this week’s Journal Digest. Read the October 14 edition: hubs.li/Q04Bcc_Q0 #JournalDigest #DermatologyResearch #Dermatology

📈 NEW DATA: New EADV 2026 findings support the use of DecisionDx-Melanoma to help inform risk-aligned sentinel lymph node biopsy decisions in patients with cutaneous melanoma. Read more: hubs.li/Q04BccH30 #Melanoma #DecisionDxMelanoma #Dermatology #EADV2026